Biowatch

Inha University Hospital Partners with Remedi to Validate Ultra-Compact, AI-Powered X-Ray Models for Frontline Care

Inha University Hospital Partners with Remedi to Validate Ultra-Compact, AI-Powered X-Ray Models for Frontline Care

Inha University Hospital has signed a memorandum of understanding with Remedi, a medical technology developer specializing in low-dose, ultra-compact...
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer

Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer

Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its CDK7-inhibiting oncology candidate,...
Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

Samsung Biologics Labor Dispute Set for Limited Q2 Impact, but Second-Half Outlook Hinges on Union Deal and U.S. Plant Costs

With wage and collective bargaining talks between Samsung Biologics and its union still unresolved, analysts expect...
Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment

Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment

Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural...
Medytox’s Neuramis Clinches China Approval, Paving Way for Dermal Filler Market Entry

Medytox’s Neuramis Clinches China Approval, Paving Way for Dermal Filler Market Entry

Medytox announced on the 25th that China’s National Medical Products Administration has granted product approval for...
Rznomics Secures U.S. Patent for Alzheimer’s RNA Therapy Candidate RZ-003

Rznomics Secures U.S. Patent for Alzheimer’s RNA Therapy Candidate RZ-003

Rznomics, a biopharmaceutical company specializing in RNA-based gene therapies, announced on the 24th that it has...
When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

When Other Biologics Fail: Skyrizi Drives Steroid-Free Remission in Over Half of Hard-to-Treat Crohn’s Patients

Crohn’s disease remains one of the most challenging inflammatory bowel diseases to manage.
From AI Medicine to K-Beauty: Medi Expo Korea 2026 Set for Record-Breaking 350-Company Showcase

From AI Medicine to K-Beauty: Medi Expo Korea 2026 Set for Record-Breaking 350-Company Showcase

MEDI EXPO KOREA 2026, a premier summer showcase of South Korea’s healthcare industry and shifting global medical...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
AI Fills the Care Gap: VUNO’s DeepCARS Cuts In-Hospital Cardiac Arrests by 21% Without Rapid Response Teams

AI Fills the Care Gap: VUNO’s DeepCARS Cuts In-Hospital Cardiac Arrests by 21% Without Rapid Response Teams

Unlike intensive care units , general hospital wards do not feature continuous, around-the-clock patient monitoring.